Data science, including the development and adoption of artificial intelligence -based methods is expected to have a transformative impact on our ability to understand disease development and trajectories. It is also expected to bring about new methods for personalized medicine in which the treatment options for patients are tailored toward the specific genetic and other characteristics of the individual. Nonetheless, there remains several and significant challenges related to the advance of data science into everyday clinical practice.
The emergence of genomic sequencing and other molecular profiling methods together with the digitalization of health care data collections have created unprecedented opportunities for better treatment options. INTERVENE is an international and interdisciplinary consortium that seeks to leverage these vast, but underused data resources to generate clinically actionable knowledge for improved understanding of diseases and treatment options tailored to individuals. Specifically, INTERVENE seeks to advance AI-facilitated analyses of complex medical data to develop genetic risk scores, which summarize the estimated effect of an individual’s genetic makeup on the risk of developing a particular disease. A central aim is to meet the urgent need for clinically validated risk scores with predictive value for complex and rare diseases, applicability for disease screening, and understandable by clinicians and citizens.
The overall objectives of INTERVENE are:
To harmonize data on more than 1.7 million genotyped / sequenced genomes with longitudinal clinical data and facilitating access to summary statistics for comparative and meta-analysis.
To develop AI-based integrative risk scores for the next generation of predictive and personalised medicine with continuous improvement and disease coverage of these scores.
To test the utility of the novel risk scores in clinical settings and develop a strategy for their implementation in Europe and beyond.